FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ in New York, NY Date:... Read More